Slide 1: Stock exchange filing cover letter
Vimta Labs Limited Registered Office: 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F : +91 40 2726 3657 VLL\SE\046\2025-26 Date: 17.07.2025 B S E Limited, National Stock Exchange of India Limited, P J Towers, Dalal Street, “Exchange Plaza”, Bandra, Mumbai: 400
Slide 2: Investor Presentation Q1 FY26
INVESTOR PRESENTATION Q1 FY26 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table Of Contents
Table Of • Q1 FY26 Earnings Contents • Company Overview • Industry Landscape • Our Competitive Advantage • Way Forward 3
Slide 5: Q1 FY26 Earnings
Q1 FY26 Earnings Section • Q1 FY26 Highlights 01 • • Key Metrics: Q1 FY26 and FY25 Profit & Loss Statement • Financial Track Record • Shareholding Pattern 4
Slide 6: Q1 FY26 Highlights
Q1 FY26 Highlights Rs 993 Mn Rs 354 Mn Rs 253 Mn Margin 35.7% Total Income EBITDA PBT Rs 4.2 Rs 241.2 Mn Rs 189 Mn Margin 19.0% CAPEX (Cash EPS PAT Outflow) 5
Slide 7: Key Metrics: Q1 FY26
Key Metrics: Q1 FY26 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 31.4% 33.1% 35.9% YoY YoY 200 YoY 19% ` 175 19% 150 19.1% 19.0% 19% 36.1% 125 35.2% 35.7% 5 100 19% 75 18% 50 18.4% 18% 266 347 354 3.1 4
Slide 8: Key Metrics: FY25
Key Metrics: FY25 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 19.1% 29.1% 725 36.8% YoY YoY YoY 20% 700 675 650 19% 625 36.2% 600 33.4% 19.2% 575 19% 550 525 500 18% 475 450 425 16.7% 400 18% 375 350 32
Slide 9: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q1 FY26 Q4 FY25 QoQ (%) Q1 FY25 YoY(%) Revenue from Operations 976 944 749 Other Income 17 16 7 Total Income 993 961 3.3% 756 31.4% Material and Testing Costs 188 182 143 Cost of lab setup 0 0 0 Changes in inventories of work-in-progress 0 0 0 Employee bene
Slide 10: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA PAT & PAT Margin Margin 36% 19% 33% 17% 29% 31% 15% 15% 11.2% 25% 25.1% 46.3% 18% 4% CAGR CAGR 10% CAGR 1,837 2,115 2,797 3,216 2,923 3,482 330 538 817 984 977 1,262 214 413 482 488 668 68 FY20 FY21 FY22 FY23 FY24 FY25 F
Slide 11: Shareholding Pattern
Shareholding Pattern Shareholding as on 30th June 2025 Share Information as on 30th June 2025 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 2,001.19 % free-float 63.30% Others Promoters 58.4% Free-float market cap (INR Cr) 1,267.35 36.7% Total Debt (INR Mn) 70.3 Cash & Cash Equivalents
Slide 12: Company Overview
Company Overview Section • Vimta at a Glance 02 • • Our Journey Our Offerings • Geographical Presence • Management 11
Slide 13: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sma
Slide 14: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & development 2024 600,000+ ft2 1300+ 492 M services; Food; Environment; Electronics Testing 3,216 M Analytical – Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; C
Slide 15: Our offerings
Our offerings Drug discovery and development services Food & Agri Testing Electronics & Electricals Testing Environment Testing & Consultancy 14
Slide 16: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Pharmaceuticals, Biologics, Medical Industry Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA
Slide 17: Food & Agri Testing
2. Food & Agri Testing Industry Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed No. of Locations 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) Accreditations & • FSSAI, ISO 17025, BIS, APEDA, EIC
Slide 18: Electricals & Electronics Testing & Certification
3. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Locations 1 (Hyderabad) Accredit
Slide 19: Environment Testing & Consultancy Services
4. Environment Testing & Consultancy Services Industry Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. No. of Locations 4 (Hyderabad, Chennai, Kolkata and Noida) Accreditations & Regulatory • MoEF, ISO 17025, QCI/NABET, OSHAS 45000 Approvals • Post pro
Slide 20: Geographical Presence
Geographical Presence Food Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Nashik Bengaluru Nellore Food Electronics & Electrical Hyderabad (Headquarters) Pharma Environment 19
Slide 21: Key Management Team
Key Management Team Harriman Vungal S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Executive Director - Executive Chairman Managing Director Executive Director Chief Financial Officer Operations • Dr. S P Vasireddi is a Scientist – • Harita has close to 25 years of • Sreenivas’
Slide 22: Industry Landscape
Industry Landscape Section • Market Opportunity 03 • Factors Driving Industry Growth 21
Slide 23: Markets Opportunity (Global)
Markets Opportunity (Global) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 14,580 14,340 36,250 9,320 7,430 3,990 25,330 (USD Mn) 9,740 Global 6,250 2,550 2025 | 2030 2024 | 2034 2025 | 2030 2025 | 2030 2023 | 2030 22
Slide 24: Markets Opportunity (Indian)
Markets Opportunity (Indian) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 309 394 1,799 460 100 (USD Mn) Indian 185 293 211 832 50 2025 | 2030 2024 | 2030 2024 | 2033 2024 | 2030 2021 | 2028 23
Slide 25: Factors Driving Industry Growth
Factors Driving Industry Growth • Increasing demand for new drug • Surge in demand for certification innovations, growth in biologics and services of electrical & electronic vaccine products development, and products, growing defence budgets increasing regulations in pharma and biotech industry and
Slide 26: Our Competitive Advantage
Our Competitive Advantage Section • Our Position in the CRTO Landscape 04 • Our Strength 25
Slide 27: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Clinical Research Electronics & Electricals • #1 in India • Among the most reputed CROs in • leading provider of EMI/EMC • Customers – 95% of top 50 in India India testing services in India • 38% revenues from overseas • 75% of revenues from overs
Slide 28: Our Strengths
Our Strengths Infrastructure Innovations Knowledge Unparalleled lab Continuous addition Multi-disciplinary, infrastructure in the of services and knowledgeable, skilled country. Gold LEED evolving excellence and trained certified Vivarium manpower Customer Centricity Compliance Technology Long term
Slide 29: Way Forward
Way Forward Section • Our Key Growth Drivers & Strategies 05 28
Slide 30: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices ✓ Growth momentum ✓ Capacity expansions ✓ Operational excellence ✓ Good corporate governance in markets ✓ Service innovations ✓ Hiring right talent ✓ Risk management ✓ Growing d
Slide 31: Thank You
THANK YOU Vimta Labs Ltd. Registered Office Siva Kambhampati | Chief Financial Officer #142, IDA Phase 2 Cherlapally, Siva.Kambhampati@vimta.com Hyderabad Telangana, India. 500051 Ernst & Young Siddesh Chawan Advait Bhadekar NSE: VIMTALABS ISIN: INE579C01029 Siddesh.Chawan@in.ey.com Advait.Bhadekar@